Corporis Medical develops the Mediclose System, a single-use suturing device designed for percutaneous suturing of port-site fascia wounds after laparoscopic surgery, and the Laprixa System, the smallest tissue blood pressure measurement device for assessing wound healing capacity. These devices enhance outcomes in minimally invasive surgeries by providing precise suturing solutions and objective, quantitative assessments of tissue healing.
Funding
$9.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Closure of port-site fascia wounds after laparoscopic surgery can be challenging, often requiring additional incisions or specialized techniques. Assessing tissue perfusion at wound sites is typically subjective, lacking quantitative measures to predict healing capacity.
Solution
Corporis Medical develops two systems designed to improve outcomes in minimally invasive surgery. The Mediclose System is a single-use suturing device for percutaneous closure of port-site fascia wounds following laparoscopic procedures, aiming to simplify and standardize the suturing process. The Laprixa System is a device for objective, quantitative assessment of tissue perfusion at the wound site.
Target Audience
The primary users are surgeons performing minimally invasive procedures, particularly laparoscopic surgeries, and healthcare providers focused on wound care and healing.
Features
- Mediclose System: Single-use device designed for percutaneous suturing of port-site fascia wounds.
- Mediclose System: Aims to simplify and standardize port-site closure.
- Laprixa System: Measures tissue blood pressure to assess wound healing capacity.
- Laprixa System: Provides objective, quantitative data for patient-specific assessment.